Table 5.
Potential Barriers to Biomarker Testing
| Access to targeted therapies118,135,137–139,143 |
| Reimbursement for testing133,138 |
| Tissue sample quality98,143 |
| TAT for test results42,120,131 |
| Coordination among multiple specialist groups126 |
| Accurate interpretation of results/physician education118 |
Abbreviation: TAT, turnaround time.